聚势谋远强管理 安全筑基稳航向——常乐制药召开十一月份经营分析会

Core Viewpoint - The meeting held by Changle Pharmaceutical Company highlighted the stable operational performance in November and emphasized the importance of strategic planning and compliance for future growth [3][4]. Group 1: Operational Performance - In November, the overall production and operation of the company remained stable, with significant improvements in product quality and production efficiency due to the upgrade of the small-volume injection workshop [3]. - The implementation of an automatic production line for inspection and packaging has effectively reduced labor intensity and supported production efficiency optimization [3]. Group 2: Compliance and Internal Control - The company identified issues in production sites through internal inspections, necessitating serious rectification and further standardization of workshop renovation approval processes [3]. - There is a strong emphasis on enhancing internal control measures, ensuring compliance in operations, and improving the standardization of business processes and approval authority [4]. Group 3: Strategic Planning and Safety - The chairman stressed the need for a clear connection between annual summaries and future planning, urging the team to analyze existing problems and develop a scientific work plan for 2026 [4]. - Safety production is a priority, with a call to learn from past incidents and conduct thorough inspections to eliminate safety hazards [4].